Infographic: Antibody Cancer Therapy

An experimental technique removes T cells that aid in vitro tumor growth.

By | April 1, 2017

© GEORGE RETSECK

TAMPING DOWN TREGS

Tumors (purple cells) recruit abnormally high numbers of potently immune-suppressing Tregs, which repress effector T cells (1) and prevent cancer destruction. Addition of anti-TNFR2 monoclonal antibodies (2) targets and kills TNFR2-expressing Tregs, thereby boosting the activity of effector T cells, which attack the tumor (3). The antibodies can also directly kill tumor cells that express the TNFR2 receptor.

Read the full story.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Edisson

Edisson

Posts: 1

June 4, 2017

Where I can read the complete text?

Avatar of: Jef

Jef

Posts: 768

Replied to a comment from Edisson made on June 4, 2017

June 5, 2017

Hi Edisson. Thanks for your interest! You can find the full story here: http://www.the-scientist.com/?articles.view/articleNo/49008/title/Targeting-Tregs-Halts-Cancer-s-Immune-Helpers/.

Thanks for reading!

Jef Akst, senior editor, The Scientist

Avatar of: Jef

Jef

Posts: 768

June 5, 2017

 

 

Hi Edisson. Thanks for your interest! You can find the full story here: http://www.the-scientist.com/?articles.view/articleNo/49008/title/Targeting-Tregs-Halts-Cancer-s-Immune-Helpers/

 

 

 

Thanks for reading!

 

 

 

Jef Akst, senior editor, The Scientist

 

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS